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Abstract
In 2012, we conducted a retrospective cross-sectional study to assess the number of people living with HIV
linked to care and, among these, the number of people on antiretroviral therapy. The health authority in each of
the 20 Italian Regions provided the list of Public Infectious Diseases Clinics providing antiretroviral therapy
and monitoring people with HIV infection. We asked every Public Infectious Diseases Clinic to report the
number of HIV-positive people diagnosed and linked to care and the number of those on antiretroviral therapy
during 2012. In 2012, 94,146 people diagnosed with HIV and linked to care were reported. The majority were
males (70.1%), Italians (84.4%), and aged between 25 and 49 years (63.4%); the probable route of transmission
was heterosexual contact in 37.5% of cases, injecting drug use in 28.1%, and male-to-male contact in 27.9%.
Among people in care, 20.1% had less than 350 CD4 cells/ll, 87.6% received antiretroviral therapy, and among
these, 62.4% had a CD4 cell count higher than 350 cells/ll. The overall estimated prevalence of individuals
diagnosed and linked to care in 2012 in Italy was 0.16 per 100 residents (all ages). Adding the estimated
proportion of undiagnosed people, the estimated HIV prevalence would range between 0.19 and 0.26 per 100
residents. In Italy, the majority of people diagnosed and linked to care receive antiretroviral therapy. A higher
prevalence of individuals diagnosed and linked to care was observed in Northern Italy and among males. More
information for developing the HIV care continuum is necessary to improve the entire engagement in care,
focusing on test-and-treat strategies to substantially reduce the proportion of people still undiagnosed or with a
detectable viral load.
Introduction
Aknowledge of the number of people living withHIV (PLHIV) is essential to address the requirements of
the national health system, plan the allocation of economic
funds, and implement prevention campaigns.
After the introduction of the antiretroviral therapy (ART)
in the mid-1990s, the number of PLHIV has notably in-
creased due to the effect of treatment that improves the sur-
vival of HIV-infected people and decreases the number of
deaths correlated with AIDS, thus transforming HIV infec-
tion into a chronic life-long infection.1 ART has improved
both the length and the quality of life of HIV-positive people
maintained on treatment. On the other hand, HIV-positive
people who are not diagnosed or engaged in the care system
cannot take advantage of these benefits, suggesting damage
not only at the individual level in terms of a faster progression
to AIDS and death, but also at the public health level in
determining the potential for ongoing transmission in a
community.2
Specifically, in recent years, gaps in the detection of HIV-
positive people among IDUs andmigrants have been reported
in Italy, in terms of both a low access to HIV testing and a
high percentage of late diagnosis.3,4
The distribution of PLHIV at various stages of the
engagement-in-care process has been synthesized in the
‘‘HIV care continuum’’ that spans from HIV acquisition to
viral suppression providing a simple quantitative depiction of
every step along the HIV care continuum2,5–8; the results of
the cascade can be used to assess the effectiveness of inter-
ventions and improve engagement in the care of HIV-positive
individuals. The steps of the HIV care continuum start with
the estimated number of HIV-infected individuals, followed
by the number of those who are diagnosed, which includes
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those linked to HIV care and those retained in care, which
includes in turn those who need ART and those who are on
ART; the cascade ends with the number of those with un-
detectable HIV viral load.6
In Italy, national data on the number of HIV-diagnosed
individuals and their characteristics (clinical, immunological,
behavioral, and treatment) are lacking, and so are the other
figures needed to describe the HIV care continuum. There-
fore, we conducted a cross-sectional study in 2012 to assess
the number of PLHIV linked to care and, among these, the
number of people on ART. These data were used also to
estimate the number of HIV-infected individuals in Italy.
Materials and Methods
In Italy, Public Infectious Diseases Clinics (PIDC) offer
monitoring and health management free of charge to all HIV-
positive individuals, including non-nationals and undocu-
mented migrants. The majority of individuals who test HIV
positive are diagnosed in PIDC and those who are tested in
other health facilities are then addressed to a PIDC for con-
firmatory testing and diagnosis. Therefore, the probability for
an individual who tests HIV positive to escape the PIDC
network is extremely low.
A law issued in 19909 in Italy established that only PIDC are
allowed to provide ART to HIV-positive individuals. ART is
offered free of charge regardless of nationality, residence, and
(for non-Italians) legal status. For these reasons, in 2012 we
decided to conduct a retrospective cross-sectional study with
the collaboration of PIDC located throughout Italy.
We contacted the regional health authority located in each
of the 20 Italian Regions and requested the list of all PIDC
providing ART and monitoring people with HIV infection in
the region. Then, every PIDC was contacted by e-mail and
asked to report (1) the number of HIV-positive people di-
agnosed and linked to care, defined as individuals who had at
least one medical visit at any time after HIV diagnosis be-
tween January 1 and December 31, 2012, and (2) the number
of HIV-positive people on ART, defined as individuals linked
to care who received and took at least one ART regimen
between January 1 and December 31, 2012.
Each of these two groups was stratified by gender (male,
female), age ( £ 24 years, 25–49 years, 50–59 years, ‡ 60
years), probable route of transmission [these groups are
mutually exclusive: heterosexuals (HET), men having sex
with men (MSM), injecting drug user (IDU), other modes
(i.e., mother-to-child transmission or blood transfusion)], last
CD4 measurement (CD4 < 200 cells/ll, CD4 200–349 cells/
ll, CD4 ‡ 350 cells/ll), and U.S. Centers for Disease Control
and Prevention (CDC) HIV clinical stage (A, B, C).
An aggregate data collection form was sent to all PIDC by
e-mail; all data were requested as aggregate numbers or
percentages of the total number of people linked to care.
After a month, each PIDC was contacted by phone to provide
quality control data. The data were confirmed by 90% of
PIDC.
The prevalence based on individuals diagnosed and linked
to care was calculated as the number of HIV-positive people
diagnosed and linked to care divided by the number of resi-
dents in Italy in 2012, per 100 (all ages). The number of
residents was obtained from the National Institute of Statis-
tics (ISTAT).10
To estimate the total number of PLHIV in Italy in 2012, we
added the estimated proportion of people either undiagnosed
or diagnosed for HIV infection but not linked to care to the
reported number of people diagnosed and linked to care.
Based on previously published data, this proportion can range
between 18% and 40%2,5,6,8,11–18 of all PLHIV. Therefore,
we calculated two estimates of the total number of PLHIV: a
minimum number considering 18% undiagnosed and a
maximum number considering 40% undiagnosed.
To make data collection less burdensome for PIDC, no
plasma viral load result or information about adherence to
ARTwas requested in the survey. However, to obtain indirect
information on these variables, we collected the proportion of
individuals with a CD4 count above 350 cells/ll among those
on ART, deemed as a proxy of those virologically suppressed
on the basis of previous findings that show that viral sup-
pression is associated with a high CD4 count.19,20
Results
In 2012, 173 PIDC were identified by the 20 regional
health authorities and were included in the survey. Of these,
170 (98.3%) agreed to participate in the study. The three
PIDC who did not participate were located in three small
towns (Fermo, Foligno, and Ragusa) accounting for 0.9% of
all Italian residents; the reason for not participating was due
in all cases to operational problems (lack of time and/or
dedicated personnel for collecting data). In 2012, these three
towns reported one new AIDS case out of 715 reported at the
national level.
Participating PIDC were geographically distributed as
follows: 38.8% in Northern Italy, 27.6% in Central Italy, and
33.6% in Southern Italy. The number of PIDC per million
residents was 2.2 per million in Northern Italy, 2.9 per million
in Central Italy, and 2.6 per million in Southern Italy. An
average number of 554 (SD– 793) people diagnosed and
linked to care by PIDC was reported: this average number
was significantly higher for PIDC located in Northern Italy
(908– 1077) compared to those in Central (453– 549) and
Southern (226– 214) Italy (Student’s t test, p < 0.001).
In 2012, 94,146 people HIV diagnosed and linked to care
were reported by the 170 participating PIDC. The majority
were males (70.1%), Italians (84.4%), and aged between 25
and 49 years (63.4%); 37.5% were HET, 28.1% IDU, 27.9%
MSM, and 6.5% reported other modes of transmission.
Among people linked to care, 10.5%had 200–349CD4 cells/ll
and 9.6% had less than 200 CD4 cells/ll (Table 1).
Among HIV-positive people diagnosed and linked to care,
87.6% received ART in 2012; of these, 68.3% were males,
85.1% were Italians, and 62.3% were aged 25–49 years. A
proportion of 37.3% HET, 28.4% IDU, 27.9% MSM, and
6.4% reporting other modes of transmission was on ART.
Among people on ART, 9.4% had a CD4 cell count below
200 cells/ll, 11.2% had 200–349 CD4 cells/ll, and 62.4%
had a CD4 higher than 350 cells/ll.
The overall estimated prevalence of PLHIV diagnosed and
linked to care in 2012 was 0.16 per 100 residents (all ages).
This proportion varied greatly by region ranging from a
minimum inMolise (0.02 per 100 residents) to a maximum in
Lombardia (0.30 per 100 residents) (Fig. 1). When adding the
proportion of infected individuals living with an undiagnosed
HIV infection or not linked to care,2,5,6,8,11–18 the total
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number of individuals HIV diagnosed and linked to care
would range from a minimum of 114,812 (including 18%
undiagnosed or not linked to care) to a maximum of 156,910
(including 40% undiagnosed or not linked to care) people.
Consequently, the estimated HIV prevalence would range
between 0.19 and 0.26 per 100 residents.
Figure 2 shows an estimate of PLHIV in Italy in 2012: the
first bar (living with HIV) shows the two estimated numbers
of PLHIV: 156,910 if 40% of PLHIV is undiagnosed and
114,812 if 18% of PLHIV is undiagnosed; of these, 94,146
people are diagnosed and linked to care; among these, 87.6%
receive ART; and among these, 62.4% have more than 350
CD4 cells/ll (missing values were not considered). The
proportion of PLHIV who have a CD4 < 350 cell count
ranges between 8.5% (when considering 156,910 PLHIV)
and 11.6 % (when considering 114,812 PLHIV). The pro-
portion is 14.1% when considering 94,146 PLHIV reporting
by PIDC.
Discussion
This is the first survey conducted in Italy aimed at defining
the number and characteristics of HIV-positive individuals
in care with the contribution of PIDC, providing an up-to-
date description of individuals living with HIV infection in
Italy. Given that PIDC treat almost all individuals diagnosed
with HIV and are the only health services authorized to
prescribe ART in Italy, the participation of almost all PIDC
guarantees a very high completeness of data regarding indi-
viduals on ART.
Although the geographic density of PIDC is similar
throughout the country, PIDC located in the north reported a
higher number of HIV-positive people in care, which is in
agreementwith the higher number of newdiagnoses of bothHIV
Table 1. Characteristics of 94,146 People Living
with HIV Diagnosed and Linked to Care
per 100 Residents in Italy in 2012
Characteristics %
Gender
Male 70.1
Female 29.9
Age, in years
£ 24 3.2
25–49 63.4
50–59 25.1
‡ 60 8.3
Nationality
Italian 84.4
Non-nationals 15.6
Transmission route
Heterosexual 37.5
IDU 28.1
MSM 27.9
Not determined 6.5
CD4 count (cells/ll)
< 200 9.6
200–349 10.5
‡ 350 79.9
AIDS diagnosis
No 73.5
Yes 26.5
People receiving ART
Yes 87.6
No 12.4
IDU, injecting drug use; MSM, men who have sex with men;
ART, antiretroviral therapy.
FIG. 1. People living with
HIV diagnosed and linked to
care in Italy, by 100 residents—
2012.
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infection and AIDS observed since the beginning of the epi-
demic in the north compared to the center and south of Italy.21
The proportion of males found in this study is more than
twice that of females, similar to what is observed for most
years in the Italian surveillance of new HIV diagnoses where
the number of males is about three times higher that of fe-
males,21 confirming that the HIV spread in Italy has been
mainly driven by male IDU, at least in the first two decades of
the epidemic.
Data obtained from the surveillance system of new HIV
diagnoses show that the peak of the HIV epidemic in Italy
occurred in the period 1986–1992,21 involving primarily in-
dividuals aged 25–30 years (these individuals would be older
than 50 years in 2012), and the median age of newly diag-
nosed HIV cases steadily increased over time.21 When
comparing these results with those obtained from this cross-
sectional study, the finding that two-thirds of the reported
population in care is younger than 50 years of age suggests a
combined effect of a high mortality rate among older cohorts
and a longer survival in the post-ART era among more re-
cently infected cohorts.
These same two factors might also explain the low pro-
portion of IDUs in care compared to both heterosexuals and
MSM: in the Italian HIV surveillance data IDUs accounted
for about 80% of all new HIV diagnoses in the period 1986–
1992 but experienced a high mortality rate before ART in-
troduction,22 whereas heterosexuals and MSM have become
prominent after 1996 (reaching 80% of all new HIV diagnoses
reported by the HIV surveillance system in 2011–2012) and
could benefit from ART.
The HIV prevalence observed in the present survey is
similar to that reported in France (0.14 per 100 residents)11
and the United Kingdom (0.15 per 100 residents),8 but lower
than that reported in the United States6,7 and Canada,14
probably reflecting a higher spread of HIV in North America
compared to Europe.
The estimated number of PLHIV of about 114,812–
156,910 is similar to the estimate (110,000–140,000) ob-
tained for Italy in 2012 using the EPP/Spectrum package
of the UNAIDS23,24: this package incorporates surveillance
data, results of prevalence surveys, and national demographic
data in a mathematical model that generates estimates of
prevalent cases and incidence trends over time. It must be
stressed that in the HIV care continuum the estimated number
of PLHIV depends on the proportion of people undiagnosed
or not linked to care.
In Italy, the proportion of undiagnosed HIV-positive
people has not been formally ascertained. A few recent
studies conducted in various Italian populations undergoing
routine HIV testing report the following proportion of HIV-
positive individuals unaware of being HIV infected: 23%
among pregnant women diagnosed in prenatal screening,25
37.5% among individuals with a sexually transmitted infec-
tion,26 and 57.1% among MSM tested in a survey conducted
in gay venues.27 However, these proportions were found in
specific subgroups and cannot be transferred to the popula-
tion at large. In addition, the higher HIV prevalence and
number of PIDC observed in Northern Italy as well as the
relevant proportion of late diagnosis among migrants in
Southern Italy4 suggest that the distribution of undiagnosed
cases may be geographically uneven across the country.
Therefore, additional information from ad hoc studies is
needed to define more accurately the proportion of undiag-
nosed HIV-positive people.
Almost 90% of people diagnosed and linked to care re-
ceive ART, which is in agreement with recent Italian HIV
treatment guidelines28 that recommend treatment initiation
regardless of CD4 count to prevent HIV transmission and
reduce the risk of disease progression. Other countries report
similar proportions of ART: 89% in the United States,5,7,29 88%
in the United Kingdom,8 83% in the Netherlands,16 and 79%
in Canada.15
HIV plasma viral suppression among treated individuals is
a crucial marker that defines the virologic success of ART,
the immunological and clinical control of the disease, and
implies a lower probability of transmitting the infection. The
FIG. 2. People living with
HIV in Italy in 2012 by di-
agnosis and treatment.
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proportion of virally suppressed individuals among those on
ART constitutes the last step of the HIV care continuum, but
this information was not included in our survey to limit data
collection to those variables that were more easily accessible
by PIDC. Using the proportion of people with CD4 ‡ 350
cells/ll among those on ART as a proxy of adherence to
treatment and consequent viral suppression, we found that
two-thirds of individuals on ART had a CD4 count ‡ 350
cells/ll: this proportion is lower than that of virally suppressed
individuals reported in other countries.5–7,18,29 However, ag-
gregate data on the last CD4 count did not make it possible to
determine if the CD4measurement was taken prior to starting
ART, when the CD4 count may be low, which may lead to
an underestimate of the number of individuals on ART with
a CD4 count ‡ 350 cells/ll. About 14.1% of PLHIV have
a CD4 cell count below 350 cells/ll stressing the need to
improve access to diagnosis and care of persons with HIV
infection.
Some limitations of this study need to be mentioned. First,
information requested to the PIDC was limited to the few
variables that were considered more relevant and easier to be
collected, which, however, hindered the depiction of all the
steps of the HIV care continuum, forcing, for example, the
replacement of the ‘‘virologically suppressed’’ proportion
with that of ‘‘CD4 > 350 cells/ll.’’ Second, data were col-
lected as aggregate data, thus hampering the check of double
counts and more detailed analyses in selected subgroups
(such as IDU and migrants who have been shown to have a
low access to HIV testing and care4). Third, the proportion of
undiagnosed or not linked to care used for calculating the first
bar of the HIV care continuum was arbitrarily defined based
on information from the literature.
Our survey shows the first estimates of HIV prevalence and
engagement in HIV care in Italy. A higher prevalence of
PLHIV diagnosed and linked to care was observed in
Northern Italy and among males; the majority of people di-
agnosed and linked to care received ART. A more accurate
description of the HIV care continuum will provide appro-
priate information for improving the entire engagement in
care; interventions should focus on test-and-treat strategies to
substantially reduce the proportion of people still undiag-
nosed or with a detectable viral load, as well as improve the
clinical outcomes and quality of life of PLHIV linked to care/
on ART with an undetectable viral load or very low CD4
count.
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